The CRISPR/Cas9 System Delivered by Extracellular Vesicles

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Mar 29

PMID 36986843

Authors

Xinglong Zhu

Mengyu Gao

Yongfeng Yang

Weimin Li

Ji Bao

Yi Li

Affiliations

Soon will be listed here.

Abstract

Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein (Cas) systems can precisely manipulate DNA sequences to change the characteristics of cells and organs, which has potential in the mechanistic research on genes and the treatment of diseases. However, clinical applications are restricted by the lack of safe, targeted and effective delivery vectors. Extracellular vesicles (EVs) are an attractive delivery platform for CRISPR/Cas9. Compared with viral and other vectors, EVs present several advantages, including safety, protection, capacity, penetrating ability, targeting ability and potential for modification. Consequently, EVs are profitably used to deliver the CRISPR/Cas9 in vivo. In this review, the advantages and disadvantages of the delivery form and vectors of the CRISPR/Cas9 are concluded. The favorable traits of EVs as vectors, such as the innate characteristics, physiological and pathological functions, safety and targeting ability of EVs, are summarized. Furthermore, in terms of the delivery of the CRISPR/Cas9 by EVs, EV sources and isolation strategies, the delivery form and loading methods of the CRISPR/Cas9 and applications have been concluded and discussed. Finally, this review provides future directions of EVs as vectors of the CRISPR/Cas9 system in clinical applications, such as the safety, capacity, consistent quality, yield and targeting ability of EVs.

Citing Articles

Optimizing therapeutic outcomes: preconditioning strategies for MSC-derived extracellular vesicles.

Song Y, Liang F, Tian W, Rayhill E, Ye L, Tian X Front Pharmacol. 2025; 16:1509418.

PMID: 39995418 PMC: 11847897. DOI: 10.3389/fphar.2025.1509418.

Control of HSV-1 Infection: Directions for the Development of CRISPR/Cas-Based Therapeutics and Diagnostics.

Sosnovtseva A, Demidova N, Klimova R, Kovalev M, Kushch A, Starodubova E Int J Mol Sci. 2024; 25(22).

PMID: 39596412 PMC: 11595115. DOI: 10.3390/ijms252212346.

Multifunctional extracellular vesicles and edaravone-loaded scaffolds for kidney tissue regeneration by activating GDNF/RET pathway.

Lee S, Park J, Rhim W, Lee E, Lee S, Kim J Nano Converg. 2024; 11(1):43.

PMID: 39460807 PMC: 11512987. DOI: 10.1186/s40580-024-00450-5.

Reporter Alleles in hiPSCs: Visual Cues on Development and Disease.

Cotta G, Teixeira Dos Santos R, Costa G, Lacerda S Int J Mol Sci. 2024; 25(20).

PMID: 39456792 PMC: 11507014. DOI: 10.3390/ijms252011009.

Exosomes target HBV-host interactions to remodel the hepatic immune microenvironment.

Wu X, Niu J, Shi Y J Nanobiotechnology. 2024; 22(1):315.

PMID: 38840207 PMC: 11151510. DOI: 10.1186/s12951-024-02544-y.

References

Lin Y, Wu J, Gu W, Huang Y, Tong Z, Huang L . Exosome-Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs. Adv Sci (Weinh). 2018; 5(4):1700611. PMC: 5908366. DOI: 10.1002/advs.201700611. View

Jinek M, Jiang F, Taylor D, Sternberg S, Kaya E, Ma E . Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science. 2014; 343(6176):1247997. PMC: 4184034. DOI: 10.1126/science.1247997. View

Holder B, Jones T, Sancho Shimizu V, Rice T, Donaldson B, Bouqueau M . Macrophage Exosomes Induce Placental Inflammatory Cytokines: A Novel Mode of Maternal-Placental Messaging. Traffic. 2015; 17(2):168-78. PMC: 4738478. DOI: 10.1111/tra.12352. View

Yang L, Chen J . A Tale of Two Moieties: Rapidly Evolving CRISPR/Cas-Based Genome Editing. Trends Biochem Sci. 2020; 45(10):874-888. DOI: 10.1016/j.tibs.2020.06.003. View

Mendt M, Kamerkar S, Sugimoto H, McAndrews K, Wu C, Gagea M . Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 2018; 3(8). PMC: 5931131. DOI: 10.1172/jci.insight.99263. View

Pickar-Oliver A, Gersbach C . The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019; 20(8):490-507. PMC: 7079207. DOI: 10.1038/s41580-019-0131-5. View

Rana S, Yue S, Stadel D, Zoller M . Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int J Biochem Cell Biol. 2012; 44(9):1574-84. DOI: 10.1016/j.biocel.2012.06.018. View

Yamamoto S, Kato A, Sakurai Y, Hada T, Harashima H . Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles. J Control Release. 2017; 251:1-10. DOI: 10.1016/j.jconrel.2017.02.010. View

Liao Y, Du X, Li J, Lonnerdal B . Human milk exosomes and their microRNAs survive digestion in vitro and are taken up by human intestinal cells. Mol Nutr Food Res. 2017; 61(11). DOI: 10.1002/mnfr.201700082. View

10.

Chen J, Li P, Zhang T, Xu Z, Huang X, Wang R . Review on Strategies and Technologies for Exosome Isolation and Purification. Front Bioeng Biotechnol. 2022; 9:811971. PMC: 8766409. DOI: 10.3389/fbioe.2021.811971. View

11.

Lainscek D, Kadunc L, Keber M, Bratkovic I, Romih R, Jerala R . Delivery of an Artificial Transcription Regulator dCas9-VPR by Extracellular Vesicles for Therapeutic Gene Activation. ACS Synth Biol. 2018; 7(12):2715-2725. DOI: 10.1021/acssynbio.8b00192. View

12.

Elahi F, Farwell D, Nolta J, Anderson J . Preclinical translation of exosomes derived from mesenchymal stem/stromal cells. Stem Cells. 2019; 38(1):15-21. PMC: 7004029. DOI: 10.1002/stem.3061. View

13.

Li L, Hu S, Chen X . Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities. Biomaterials. 2018; 171:207-218. PMC: 5944364. DOI: 10.1016/j.biomaterials.2018.04.031. View

14.

Morad G, Carman C, Hagedorn E, Perlin J, Zon L, Mustafaoglu N . Tumor-Derived Extracellular Vesicles Breach the Intact Blood-Brain Barrier Transcytosis. ACS Nano. 2019; 13(12):13853-13865. PMC: 7169949. DOI: 10.1021/acsnano.9b04397. View

15.

Whitley J, Kim S, Lou L, Ye C, Alsaidan O, Sulejmani E . Encapsulating Cas9 into extracellular vesicles by protein myristoylation. J Extracell Vesicles. 2022; 11(4):e12196. PMC: 8982324. DOI: 10.1002/jev2.12196. View

16.

Wang Q, Yu J, Kadungure T, Beyene J, Zhang H, Lu Q . ARMMs as a versatile platform for intracellular delivery of macromolecules. Nat Commun. 2018; 9(1):960. PMC: 5840177. DOI: 10.1038/s41467-018-03390-x. View

17.

Jiang X, Zhang T, Gao J . The in vivo fate and targeting engineering of crossover vesicle-based gene delivery system. Adv Drug Deliv Rev. 2022; 187:114324. DOI: 10.1016/j.addr.2022.114324. View

18.

Raimondo S, Saieva L, Corrado C, Fontana S, Flugy A, Rizzo A . Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism. Cell Commun Signal. 2015; 13:8. PMC: 4320527. DOI: 10.1186/s12964-015-0086-x. View

19.

Wan T, Zhong J, Pan Q, Zhou T, Ping Y, Liu X . Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases. Sci Adv. 2022; 8(37):eabp9435. PMC: 9473578. DOI: 10.1126/sciadv.abp9435. View

20.

Gao R, Luo Q, Li Y, Song L, Cai J, Xiong Y . Biosynthetic Nanobubble-Mediated CRISPR/Cas9 Gene Editing of Cdh2 Inhibits Breast Cancer Metastasis. Pharmaceutics. 2022; 14(7). PMC: 9319454. DOI: 10.3390/pharmaceutics14071382. View